ROSY-F: Roll-Over Study for Participants Who Have Completed a Previous Study with Benralizumab (Fasenra) and Are Judged by the Investigator to Clinically Benefit from Continued Treatment
Denmark, Belgium, France, Italy, Netherlands, Austria, Poland
Condition studied
Eosinophilic Granulomatosis with Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES), Asthma
Investigational medicinal product(s)
Fasenra 30 mg solution for injection in pre-filled syringeBenralizumab
Eligibility
Age group
65+ years, 0-17 years, 18-64 years
Sex
Female, Male
Primary endpoint
Safety will be evaluated by monitoring and assessing SAEs and non-serious AEs reported throughout the study and until 8 weeks after the last dose of benralizumab.
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.